Navigation Links
Treatment with the Zevalin(R) Therapeutic Regimen as Sole Therapy Produces 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma
Date:1/22/2009

isks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of Zevalin include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with Zevalin in particular including, without limitation, the potential for Zevalin to be proved safe and effective for the treatment of additional indications as noted in this publication or any other indication, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, and costs of developing, producing and selling Zevalin. You should also review the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

     Media Contact:
     Dan Eramian
     T: 206.272.4343
     C: 206.854.1200
     E: media@ctiseattle.com
    http://www.CellTherapeutics.com/press_room

     Investors Contact:
     Ed Bell
     T: 206.272.4345
     Lindsey Jesch Logan
     T: 206.272.4347
     F: 206.272.4434
     E: invest@ctiseattle.com
    http://www.CellTherapeutics.com/investors

'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. New treatment effective in counteracting cocaine-induced symptoms
2. New treatment boosts muscle function in myasthenia gravis
3. Broad-based group of physicians calls for improvement in stroke treatment
4. Cranberry Could Juice Up Ovarian Cancer Treatment
5. Non-medicinal treatment touted for pre-schoolers with ADHD
6. Nonmedicinal treatment touted for preschoolers with ADHD
7. U of M study: Early treatment can reverse heart damage
8. Biologic treatment for rheumatoid arthritis and the risk of cancer
9. New Treatment Explored for Cluster Headaches
10. Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri
11. 4-Star Gen. Barry Mccaffrey, Former U.S. Drug Czar, to Keynote Recovery Happens! Rally for Treatment: Wed., Sept. 5, 11 Am, State Capitol West Steps, Sacramento
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Mike Lucas of GE Healthcare Recognized as the Lifeline for Minority Businesses; Receives the MMBDC 2009 President's Award 2Health News:Concord Grape Juice Shown to Help Keep Hearts and Minds Healthy 2Health News:Concord Grape Juice Shown to Help Keep Hearts and Minds Healthy 3Health News:Concord Grape Juice Shown to Help Keep Hearts and Minds Healthy 4Health News:The Concord Grape Commands Attention at Major Scientific Conference 2Health News:The Concord Grape Commands Attention at Major Scientific Conference 3Health News:The Concord Grape Commands Attention at Major Scientific Conference 4Health News:The Concord Grape Commands Attention at Major Scientific Conference 5Health News:The Kenneth Rainin Foundation Awards $457,000 in Grants to Support Dance, Theater, Film and Early Literacy in the San Francisco Bay Area 2Health News:The Kenneth Rainin Foundation Awards $457,000 in Grants to Support Dance, Theater, Film and Early Literacy in the San Francisco Bay Area 3Health News:Video Contest With $5,000 CASH Prize!!! 2
Breaking Medicine Technology:Millstone Medical Outsourcing Appoints New Leadership of Memphis Facility 2St. Luke's Hospital Acquires Pioneering Technology From BrainLAB 2St. Luke's Hospital Acquires Pioneering Technology From BrainLAB 3AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting 5506 1Aethlon Medical Announces Presentation of Hepatitis C 28HCV 29 Clinical Data at 42nd Annual American Society of Nephrology 28ASN 29 Conference 5503 1Aethlon Medical Announces Presentation of Hepatitis C 28HCV 29 Clinical Data at 42nd Annual American Society of Nephrology 28ASN 29 Conference 5503 2Aethlon Medical Announces Presentation of Hepatitis C 28HCV 29 Clinical Data at 42nd Annual American Society of Nephrology 28ASN 29 Conference 5503 3CREON 28R 29 28pancrelipase 29 Delayed Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 5500 1CREON 28R 29 28pancrelipase 29 Delayed Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 5500 2CREON 28R 29 28pancrelipase 29 Delayed Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 5500 3CREON 28R 29 28pancrelipase 29 Delayed Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 5500 4CREON 28R 29 28pancrelipase 29 Delayed Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 5500 5CREON 28R 29 28pancrelipase 29 Delayed Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 5500 6